Page 62 - MEMOCiberer014-ENG

PROTEOmAb
PROTEOmAb is an energy metabolism phenotyping platform using protein array technology . It is located in CIBERER unit U713 Centro de Biología Molecular Severo Ochoa UAM and is led by Dr . José María Cuezva . The group has ample experience in this methodology that it has been offering as a service to the scientific community since 2012 . It offers a service comprising the quantitative analysis of energy metabolism proteins in biological samples in a simple and reproducible manner using high-affinity and high-specificity monoclonal antibodies (mAbs) .
METHODOLOGY: The analyses can be done on collections of up to 1,000 different biopsies, which allows establishing correlations with clinical parameters and parameters of response to certain treatments . A reverse-phase protein microarray platform is used, which allows quantifying the expression of energy metabolism proteins in biopsies of normal and pathological tissues .
PROTEOMAB SERVICES:
• Identification and validation of molecular markers of the disease and of the response to therapy . • Identification of new diagnostic markers . • Establishing correlations between biomarkers and disease progression . • Establishing correlations between biomarkers and response to a specific treatment .
PROTEOMAB COLLABORATIONS/SERVICE DEVELOPED
Collaborations have been established with various CIBER groups and with other institutions:
• Dr . Francesc Palau-U732 . -Pathology studied: Charcot-Marie Tooth .
• Dr . José María Millán-U755 .- Pathology studied: Retinitis Pigmentosa .
• Dr . Lourdes Ruiz Desviat-U746 and Dr . Barry Michel, Clinical Mayo, Rochester, USA . Pathology studied: Propionic acidemia .
• Dr . Francesc Cardellach-U722 . Pathology studied: Myositis in all its variants: dermatomyositis, polymyositis and myositis with inclusion bodies .
• Dr . Miguel A . Martín Casanueva-U723 . Pathology studied: Mitochondriopathies due to Complex I deficiency .
62
CIBERER » Annual report 2014